Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Perrigo

FDA panel backs over-the-counter birth control pill

Federal health advisers are recommending that a decades-old birth control pill be sold without a prescription

The Independent UK

The FDA considers first birth control pill without a prescription

The FDA considers first birth control pill without a prescription

The Food and Drug Administration is weighing whether to allow a birth control pill to be sold over the counter for the first time. An advisory committee opens a two-day hearing Tuesday.

FDA weighing 1st over-the-counter birth control pill

FDA weighing 1st over-the-counter birth control pill

U.S. health regulators are weighing the first-ever request to make a birth control pill available without a prescription

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA sets date to review first US over-the-counter birth control

U.S. regulators will hold a joint meeting in May to review whether Perrigo Co.’s birth-control product Opill can be sold without a prescription.

Tribune News Service

Why this company has spent nine years trying to sell birth control pills without a prescription

HRA Pharma hasn't given up on the long-shot goal.

U.S. women still can’t get birth control pills over the counter. Inside one company's 9-year struggle to change that

Post-Roe, women’s access to contraception is more important than ever. But Perrigo's HRA Pharma is still waiting to hear back from the FDA.

FDA delays advisory committee meeting on over-the-counter birth control pill

WASHINGTON — The Food and Drug Administration on Wednesday postponed a critical advisory meeting on an application for the nation’s first over-the-counter birth control pill, citing the need “to review new information.”

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA delays key advisory committee meeting on OTC birth control - Roll Call

FDA delays key advisory committee meeting on OTC birth control - Roll Call

The delay comes as Democrats agitate for increased access to birth control in the wake of the Supreme Court decision overturning Roe v. Wade.

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

The ruling by the U.S. Supreme Court to overturn Roe v. Wade and leave the decision of abortion to the states has been a big topic over the last few days. An analyst singles out a pharmaceutical company that could benefit from increased purchases of over-the-counter contraceptives.

Shortages mean higher profit margins for baby formula makers

Shortages mean higher profit margins for baby formula makers

While shortages have tormented parents, baby formula makers are recording higher profit margins.

Is Perrigo a Buy After Reporting Q1 Earnings?

Is Perrigo a Buy After Reporting Q1 Earnings?

The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to…

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

Perrigo Clocks 5% Sales Growth In Q4, Bottom-Line Surpass Expectation

Perrigo Company plc (NYSE: PRGO)

Get all your
news in one place.

100's of premium titles.
One news app.

Perrigo: Q4 Earnings Insights

Perrigo (NYSE:PRGO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

1 2

People

Jack Resneck Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

the Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

406,712 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play